IMPROVED DISEASE FREE SURVIVAL IN JMML. THE DUTCH EXPERIENCE.
Background and Aims: Since the start of the Princess Máxima Center in June 2018, we treat all Dutch patients with JMML. Our patients have shown a good outcome as compared to patient cohorts described in the literature and our aim was to present the clinical and molecular characteristics, treatment and outcome of these children.
Authors
- Marco J. Koudijs
- Merel O. Mol (ORCID: https://orcid.org/0000-0003-2533-2530)
- Wijnanda A. Kors (ORCID: https://orcid.org/0000-0002-6574-8023)
- Esmé Waanders (ORCID: https://orcid.org/0000-0002-2466-953X)
- Kirsten A. Thus
- Dorine Bresters (ORCID: https://orcid.org/0000-0002-5417-4159)
- Marc Bierings (ORCID: https://orcid.org/0000-0002-0192-3080)
- Mirjam E. Belderbos (ORCID: https://orcid.org/0000-0002-6164-2918)
- Válerie de Haas (ORCID: https://orcid.org/0000-0003-0339-6816)
- Katja Heitink
Institutions
- University Medical Center Utrecht (NL)
- Princess Máxima Center (NL)
Publication Details
- Journal
- EJC Paediatric Oncology
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1016/j.ejcped.2025.100383
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00